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INTRODUCTION: The tumour microenvironment is hypoglycaemic, hypoxic and acidotic. This activates a stress signalling pathway: the
unfolded protein response (UPR). The UPR is cytoprotective if the stressor is mild, but may initiate apoptosis if severe.
Activation of the UPR in breast carcinoma is induced by microenvironmental stress such as glucose and oxygen deprivation, but may
also be linked to oestrogen stimulation. It may be clinically significant as it may alter chemosensitivity to doxorubicin.
METHODS: 395 human breast adenocarcinomas were immunohistochemically stained for UPR activation markers (glucose-regulated
protein (GRP-78 and XBP-1). A model of UPR activation in vitro by glucose deprivation of T47D breast cancer cells was developed to
determine how the UPR affects cellular sensitivity to doxorubicin and 5-fluorouracil. Cytotoxicity was assessed using a colorimetric
cytotoxicity assay (MTT). The effect of oestrogen stimulation and tamoxifen exposure on UPR activation by T47D cells was
determined by western blotting measurement of the key UPR protein, GRP-78.
RESULTS: Expression of GRP78 and XBP-1 was demonstrated in 76% and 90% of the breast cancers, respectively, and correlated with
oestrogen receptor positivity (P¼ 0.045 and 0.017, respectively). In vitro UPR activation induced resistance to both doxorubicin and
5-flurouracil, (Po0.05). Oestrogen stimulation induced GRP78 and XBP1 over-expression on western blotting. Tamoxifen did not
block this response and may induce UPR activation in its own right.
CONCLUSIONS: The UPR is activated in the majority of breast cancers and confers resistance to chemotherapy. In vitro oestrogen
stimulates UPR induction. UPR activation may contribute to breast cancer chemoresistance and interact with oestrogen response
elements.
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The unfolded protein response (UPR), is a stress response pathway
whose physiological function is to safeguard the synthesis of
normal cellular proteins (Scriven et al, 2007a). Protein synthesis in
the endoplasmic reticulum is a vital component of cellular activity.
Controlling the quality of protein products exported from the
endoplasmic reticulum to the remainder of the cell is critical to
ensuring normal cellular function (Hammond and Helenius, 1994).
Proteins are synthesised initially as simple, linear, polypeptide
chains and subsequently undergo a complex glycosylation and
folding process before assuming the correct functional conforma-
tion. Folding is an energy-dependent process and incorrect folding
or glycosylation may occur in the presence of glucose deprivation.
This leads to the accumulation of malfolded or incompletely folded
proteins in the endoplasmic reticulum. These ‘unfinished’ proteins
are bound to chaperone molecules such as glucose-regulated
protein 78 (GRP 78) to prevent their export from the endoplasmic
reticulum whence they might disrupt cellular function (Wei and
Hendershot, 1995). The cell has mechanisms to detect increased
levels of malfolded proteins and will then initiate the UPR
(Kozutsumi et al, 1988).
This UPR pathway has wide ranging cellular effects including
(Scriven et al, 2007a):
1. Reduced global protein synthesis and cell-cycle arrest.
2. Activation of UPR responsive genes.
3. Inhibition of apoptosis if the stress is mild or reversible.
4. Initiation of apoptotic pathways if the stress is severe or
prolonged.
Human solid tumours contain areas of poor vascular perfusion,
which result from inadequacies in the tumour microcirculation
and cancer cells preferentially use glucose as an energy source –
the Warburg effect (Warburg, 1956). The net result is that human
tumours typically exist in an environment of glucose and oxygen
deprivation. Although tumour cells may undergo necrosis or
apoptosis if these conditions are severe, they have cellular survival
strategies, which enable them to withstand these severe conditions
(for example induction of angiogenesis and the UPR). Under
conditions of mild to moderate stress, the UPR is anti-apoptotic
and enables cells to withstand such stressful stimuli and it has
recently been shown that UPR induction is vital for allowing cells
to withstand periods of hypoxia (Koumenis and Wouters, 2006).
This ability of the UPR to protect cells (including cancer cells)
from adverse conditions underpins its clinical significance.
Revised 27 August 2009; accepted 17 September 2009; published online
27 October 2009
*Correspondence: L Wyld; E-mail: l.wyld@sheffield.ac.uk
British Journal of Cancer (2009) 101, 1692 – 1698
& 2009 Cancer Research UK All rights reserved 0007 – 0920/09 $32.00
www.bjcancer.com
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
The UPR is potentially important in the field of oncology for a
number of reasons. The UPR is activated in a range of human solid
tumours including breast cancer (Fernandez et al, 2000), gastric
cancer (Zhang et al, 2006; Scriven et al, 2007b), hepatocellular
carcinoma (Shuda et al, 2003; Al-Rawashdeh et al, 2008),
pancreatic cancer (Scriven et al, 2008) and lung cancer (Uramoto
et al, 2005).
A link has been shown between UPR activation and poor clinical
outcome, with glucose-deprived tumours having increased meta-
static potential (Schlappack et al, 1991). High levels of GRP78
expression correlate with increasing tumour grade in hepato-
cellular carcinoma (Shuda et al, 2003), poor clinical outcome in
breast cancer (Lee et al, 2006), higher recurrence and mortality
rates in prostate cancer (Daneshmand et al, 2007) and a higher rate
of nodal metastasis and reduced survival in gastric cancer (Zhang
et al, 2006).
Over-expression of the UPR may also be clinically important
because it reduces the efficacy of certain types of chemotherapy,
such as doxorubicin (Shen et al, 1987; Hughes et al, 1989;
Chatterjee et al, 1995), one of the mainstays of most breast cancer
chemotherapy regimens. The UPR also interacts with oestrogen
responsive pathways in breast cancer and has recently been
proposed to contribute to the development of anti-oestrogen
resistance (Fu et al, 2007; Gomez et al, 2007; Davies et al, 2008).
It is therefore likely that the high level of UPR activation in
human breast cancers will be of clinical significance, because of the
inhibition of chemosensitivity and its potential role in the
development of anti-oestrogen resistance. The aims of this study
were to further clarify these associations.
MATERIALS AND METHODS
Materials
Anti-GRP78 goat polyclonal antibody (sc-1050, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), anti-XBP-1 rabbit
polyclonal antibody (cat no. 619501, BioLegend, San Diego, CA,
USA), Vectastain ABC elite goat and rabbit kits (Vector
Laboratories Inc., Burlingame, CA, USA), anti-GRP78 mouse
monoclonal antibody (cat no 610979, BD Biosciences, San Jose,
CA, USA), anti-XBP-1 mouse polyclonal antibody (H7494-B01,
Abnova, Taipei, Taiwan) and recombinant positive control
H7494-P01 (54 kDa), anti-hypoxia inducible factor-1a (HIF-1a)
mouse monoclonal antibody (cat no 61095, BD Biosciences)
b-actin mouse monoclonal antibody (Sigma Aldrich Company
Ltd, Dorset, UK), RPMI 1640 and glucose-free RPMI 1640 media
(Invitrogen Corporation, Carlsbad, CA, USA), dialysed fetal bovine
serum (FBS) (Sigma Aldrich Company Ltd), penicillin and
streptomycin (Lonza Group Ltd, Basel, Switzerland), D-glucose
anhydrous (Sigma Aldrich Company Ltd), 5-fluorouracil (Sigma
Aldrich Company Ltd), doxorubicin hydrochloride (Sigma Aldrich
Company Ltd), 17b-oestradiol (Sigma Aldrich Company Ltd).
Immunohistochemistry
Sample collection and preparation Appropriate ethical commit-
tee approval was obtained (SSREC/02/155 and SSREC 04/Q2305/
67); 395 cases of breast cancer were identified. The tumour areas
were identified and sampled in triplicate with a 0.6mm diameter
tissue array punch (Beecher Instruments Inc., Sun Prairie, WI,
USA) to create a tissue micro array. Each case was given a unique
identifier and linked to a database containing clinico-pathological
data. The completed array contains 296 ductal, 39 lobular, 21
tubular and 39 other histological types.
Ten cases of DCIS were identified and sequential sections cut
from a formalin-fixed paraffin-embedded sample and stained for
GRP78, XBP1 and the marker of hypoxia HIF-1a.
Immunohistochemistry method Staining for GRP78 and XBP-1
proteins was performed using the avidin–biotin–peroxidase
complex method (Hsu et al, 1981). For antigen retrieval the
sections where immersed in 0.01 M tris–sodium citrate adjusted to
pH 6.0 and boiled for 10min followed by 10min simmering at
751C. Slides were incubated with anti-GRP78 or anti-XBP1 primary
antibody (both at 1 : 100) for 30min at room temperature and then
washed in phosphate-buffered saline. Biotinylated anti-goat or
anti-rabbit IgG was used as a secondary antibody and visualised
with diaminobenzidine. For each antibody, three slides were
stained representing triplicate samples from each case and scored
semi-quantitatively: 0 negative, 1 weak positive, 2 intermediate
positive and 3 strongly positive. Scores were totalled across the
three cores; cases with only one core present were excluded, cases
with two viable scores had the third missing score replaced with
the mean of the two viable cores. Scoring was performed by
SSC – an experienced breast disease histopathologist and PS. The
correlation coefficient for scoring of cores between the two
observers was high (GRP78 r¼ 0.978, for XBP1 r¼ 0.956).
For HIF-1a staining on the DCIS sections antigen retrieval used
the DAKO Target retrieval solution and the DAKO Catalysed
Signal Amplification kit. Three sequential sections of each case
were stained for GRP78, XBP1 and HIF-1a.
In vitro studies
Validation and method of in vitro model of UPR induction
Cell culture: The human breast cancer cell line T47D was
obtained from the European Collection of Animal Cell Cultures
(ECACC) and maintained in RPMI 1640 with 10% dialysed FBS,
1% L-glutamine and 1% penicillin and streptomycin at 371C in 5%
CO2 humidified air. For glucose deprivation experiments glucose-
free RPMI 1640 was supplemented with D-glucose to yield media
with glucose concentrations of 1, 0.5 and 0.2mmol. Cells were
seeded into standard T75 culture flasks and allowed to settle for
24 h in standard media. The media was then exchanged for
glucose-deprived media and flasks left for 24, 48 and 72 h before
lysing cells for western blotting.
For oestrogen stimulation experiments, cells were grown in
standard media supplemented with 0.5, 1 and 5 nM of 17b-
oestradiol. One nanomolar 17b-oestradiol represents a concentra-
tion that would be expected in a normal premenopausal female
and has previously been shown to induce GRP78 (Gilligan et al,
1994; Kiang et al, 1997) Flasks were lysed after 24 and 48 h
exposure.
Tamoxifen was dissolved in DMSO to yield a 1mM solution,
which was then serially diluted with RPMI 1640 media to yield
working concentrations of 1, 10 and 50 mM tamoxifen in 0.1%
DMSO; 0.1% DMSO does not have any effect on the growth of
T47D cells (Lim et al, 2006). Cells were exposed for 24 and 48 h
before lysing.
Western blot analysis: Cells were lysed in triple detergent lysis
buffer (0.1% sodium dodecyl sulphate, 1% nonidet P-40, 0.5%
sodium deoxycholate) and complete EDTA-free protease inhibitor
cocktail (F. Hoffmann-La Roche AG, Basel, Switzerland) on ice
and centrifuged at 13 000 r.p.m. for 10min to remove insoluble
material. The supernatant was stored at 80oC. Whole cell lysates
and recombinant GRP78 protein as a positive control (gifted by Dr
Valerie Corrigal, Kings College London) were electrophoretically
separated through a 10% SDS–polyacrylamide gel and blotted
onto PVDF membrane (Millipore Inc., Billerica, MA, USA).
Antibodies for western blotting were anti-GRP78 (BD Biosciences)
1 : 1000, anti-XBP1 detecting the 54 kDa spliced variant (Abnova)
1 : 1000 and anti-b-actin 1 : 10 000. Appropriate horseradish
peroxidase-conjugated IgGs were used as secondary antibodies.
Blots were developed with SuperSignal West Dura Extended
Duration Substrate (Thermo Scientific Inc., Waltham, MA, USA)
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and imaged with a Syngene CCD imaging system (Synoptic Ltd,
Cambridge, UK). Bio-Rad Quantity One (Bio-Rad Laboratories
Inc., Hercules, CA, USA) software was used on the raw image to
allow semi-quantitation of blot signal intensity relative to the actin
signal intensity. A minimum of three blots for each experimental
arm was performed.
Chemosensitivity assay: The colourimetric thiazolyl blue tetra-
zolium bromide (MTT) assay was used to determine response to
chemotherapy agents. Reduction of MTT by mitochondrial
dehydrogenase enzymes produces purple formazan crystals, which
can be solubilised by DMSO and quantified by absorbance
photometry. An optimum seeding density of 37 500 per cells cm2
was determined and 96-well plates were seeded accordingly.
Inhibitory concentration 50 (IC50) doses of doxorubicin and
5-FU were determined for cells in standard culture conditions.
Subsequently 96-well plates were seeded and after 24 h the media
exchanged for glucose-deprived media and a further 24 h later the
IC50 dose of either doxorubicin or 5-FU applied and the plate read
48 h later. The relative percentage viability for each glucose
concentration was then calculated. Each arm comprised three
triplicate repeats.
Statistical analysis: Statistical analysis was performed using SPSS
version 15 (SPSS Inc., Chicago, IL, USA) Statistical significance
was set at Po0.05.
RESULTS
Immunohistochemistry
Of the ex-vivo breast cancer samples on the tissue micro array,
76% stained strongly (score 46/9) for GRP78 and 90% stained
Figure 1 Representative photmicrographs of GRP78-stained breast tissue cores from the TMA (magnification  40). (A) Negatively stained normal
breast tissue, (B) weakly stained core score 1, (C) intermediately stained core scores 2, (D) strongly stained core scores 3.
Figure 2 Representative photomicrographs of DCIS stained for
GRP78, HIF-1a and XBP1 (magnification  40). Immunohistochemical
staining of a representative DCIS specimen. (A) Is stained for GRP78 a
marker of UPR activation and (B) is stained for HIF-1a, a marker
of response to hypoxia.
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strongly for XBP1. Normal tissue on the array did not stain for
either protein. Figure 1 shows representative sample cores of
non-staining, weakly staining, intermediate and strongly staining
cores. GRP78 is principally distributed within the cytoplasmic
regions, XBP1 is distributed in both the cytoplasmic and nuclear
regions of cells, as would be expected from their known biological
mechanisms of action (Scriven et al, 2007a).
All 10 DCIS sections stained positive in tumour regions for
GRP78, 8 of 10 had detectable nuclear XBP1 staining. Adjacent
normal breast tissue did not stain for either GRP78 or XBP1 in
keeping with the findings of the tissue micro array. HIF-1a staining
was observed in seven samples of which all showed co-expression
in tumour regions with GRP78 and six showed co-expression of all
three proteins in tumour regions. (Figure 2 shows a representative
section stained for GRP78 and HIF-1a).
High GRP78 and XBP1 scores were associated with oestrogen
receptor (ER) positivity (P¼ 0.045 and 0.017, respectively). There
was no statistically significant correlation with tumour size, grade,
lymph node metastases, vascular invasion, histological type or
Nottingham Prognostic Index (Haybittle et al, 1982).
High GRP78 scores correlated with high XBP1 scores P¼o0.01
(Spearman’s correlation coefficient).
In vitro model of UPR induction by glucose deprivation
Culture under conditions of progressive glucose deprivation for
24 and 48 h induced expression of GRP78 on western blotting
(Figure 3A). XBP1 is detectable in all glucose-deprived samples but
not in lysates from standard culture conditions (Figure 3C).
Analysis of raw image data using Bio-Rad Quantity One for a
minimum of three blots confirms increasing signal density in
glucose-deprived lysates compared with normal controls.
In vitro oestrogen stimulation
Exposure to 0.5, 1 and 5 nM 17-b-oestradiol for 24 and 48 h induces
GRP78 expression in a dose-dependant manner compared with
standard non-stimulated cells (Figure 3B). XBP1 is detectable in all
oestrogen-stimulated samples but not in lysates from standard
culture conditions (Figure 3C). Analysis of raw image data using
Bio-Rad Quantity One for a minimum of three blots confirms
increasing signal density in oestrogen-stimulated lysates compared
with normal controls.
The in vitro effect of tamoxifen
Exposure to a range of tamoxifen doses (1, 5, 10, 15, 20 mM) did
not block the UPR activating effect of oestrogen stimulation
(Figure 4A). In fact, tamoxifen exposure alone is sufficient to
induce UPR activation (Figure 4B).
In vitro cytotoxicity
Under standard culture conditions the IC50 (inhibitory concentra-
tion 50%) dose of 5-FU was determined to be 20 mgml1 and for
doxorubicin 3 mgml1 (data not shown). Figure 5 shows that
glucose deprivation significantly enhanced resistance to the IC50
Recombinant
positive controls 
Grp78
Actin 
Grp78
Actin 
Actin
XBP1
Standard
glucose 1 mM glucose 0.5 mM glucose 0.2 mM glucose
Standard
media 5 nM Oestrogen1 nM Oestrogen0.5 nM Oestrogen
Standard
media 
1 mM
glucose 
0.5 mM
glucose 
0.2 mM
glucose 
0.5nM
Oestrogen 
1 nM
Oestrogen 
5 nM
Oestrogen 
40 kDa
50 kDa
Figure 3 Induction of GRP78 and XBP1 by glucose deprivation and oestrogen stimulation. Western blots of breast cancer cell line lysates (T47D) after
exposure to varying culture conditions to demonstrate GRP78 or XBP1 expression. (A) Cells cultured in differing glucose concentrations varying from
normal to 0.2mM showing progressively increasing GRP78 levels as glucose concentrations fall. (B) Cells cultured in progressively increasing oestrogen
concentrations showing GRP78 over-expression. (C) Cells cultured in varying glucose or oestrogen concentrations showed that lack of glucose or oestrogen
stimulation induced XBP1 expression.
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dose of both 5-FU and doxorubicin when compared with cells
cultured under normal glucose conditions (P¼ 0.001 for 5-FU and
P¼ 0.008 for doxorubicin, respectively).
DISCUSSION
Activation of the UPR has been reported in a wide variety of
cancers, and there is extensive evidence for its in vivo activation
in human tumours, (Fernandez et al, 2000; Shuda et al, 2003;
Uramoto et al, 2005; Zhang et al, 2006; Scriven et al, 2007b;
Al-Rawashdeh et al, 2008; Scriven et al, 2008).
This study is the largest series of breast cancer cases showing
UPR activation as shown by upregulation of GRP78 and that a key
downstream effector of the UPR, XBP1, is also over-expressed.
The percentage of breast cancers that show UPR induction in
our data (78% over-express GRP78) is similar to that shown by
other researchers; 67% of breast cancers were found to over-
express GRP-78 in a study by Lee et al (2006). The present data did
not show any association between standard prognostic factors for
breast cancer such as grade, nodal status and Nottingham
Prognostic Index. This is not surprising given the high percentage
of positive expression found and the relative insensitivity of semi-
quantitatively scored immunohistochemistry for quantitation of
protein levels. More precise study of this association might be
provided by mRNA expression measurement using q-PCR.
This study is the first to show an association between both
GRP78 and XBP-1 with increasing ER positivity in clinical breast
cancer samples. A possible link between oestrogen stimulation and
the UPR was first suggested in 1997 using breast cancer cell lines
(Kiang et al, 1997). Gene expression profiling of ex-vivo breast
cancer tissue has previously shown an association between ER
expression and XBP-1 expression, (Sørlie et al, 2001). Fernandez
et al analysed a small (n¼ 25) sample of breast cancers and found
over-expression of GRP78 on western blotting in four of six
ER-positive tumours and three of three ER-negative tumours. The
sample size is too small to confidently assert that there is an
association with GRP78 over-expression in ER-negative tumours
(Fernandez et al, 2000).
There is little current understanding of the link between the two
pathways. There is speculation that activation of the UPR may be
associated with the development of anti-oestrogen resistance
(Fu et al, 2007; Gomez et al, 2007). UPR induction reduces the
occurrence of apoptosis in oestrogen-dependent breast cancer cells
treated by oestrogen withdrawal, (which clinically correlates with
the use of aromatase inhibitors, Fu et al, 2007). Over-expression of
XBP-1, another marker of UPR activity, is correlated with
resistance to the apoptotic and anti-proliferative effects of anti-
oestrogens, (Davies et al, 2008). The UPR-activated splice variant
of XBP-1, (XBP-1s), confers anti-oestrogen resistance and oestro-
gen-independent growth in breast cancer cell lines in vitro (Gomez
et al, 2007).
The findings of this study further support a link between the
UPR and oestrogenic stimulation. Oestrogenic stimulation in
otherwise ideal culture conditions is sufficient to activate the UPR
Grp78
Actin 
1            2            3             4            5            6            7 
1            2          3           4          5           6           7           8
Grp78 
Actin 
Figure 4 The effect of tamoxifen on T47D cells cultured in oestrogen-
supplemented media. Western blots of cancer cell line (T47D) lysates after
culture under different conditions. (A) Lane plan: 1: standard culture
conditions; 2: 0.1% DMSO-supplemented media; 3: 1 nM oestrogen-
supplemented media; 4: 1 nM oestrogen plus 1 mM tamoxifen-supplemented
media; 5: 1 nM oestrogen plus 5 mM tamoxifen-supplemented media; 6: 1 nM
oestrogen plus 10mM tamoxifen-supplemented media; 7: 1 nM oestrogen
plus 15mM tamoxifen-supplemented media; 8: 1 nM oestrogen plus 20mM
tamoxifen-supplemented media; (B) lane plan: 1: standard culture
conditions; 2: standard conditions þ 0.1% DMSO; 3: 1 mM tamoxifen-
supplemented media; 4: 5mM tamoxifen-supplemented media; 5: 10mM
tamoxifen-supplemented media; 6: 15mM tamoxifen-supplemented media;
7: 20mM tamoxifen-supplemented media.
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Figure 5 Relative % toxicity for T47D cells under normal and glucose-deprived culture conditions when exposed to previously determined IC50 doses of
doxorubicin (A) and 5-FU (B). Relative % survival (mean þ / s.e.m.) for T47D cells under normal and glucose-deprived culture conditions when exposed
to 3 mgml1 doxorubicin (A) and 20mgml1 5-FU (B). Survival is significantly higher under conditions of low glucose compared with standard culture
conditions. Data derived from three triplicate repeats, *P¼o0.05.
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as shown by GRP78 over-expression. These data support the 1997
findings of Kiang and colleagues. The data presented here also
extend this by showing for the first time that oestrogenic
stimulation is also sufficient to induce downstream effectors of
UPR activation such as XBP1. The data shown here are derived
from cell culture using phenol red containing RPMI 1640. Phenol
red is known to have weak oestrogenic effects. It binds to ERs with
an affinity 0.001% of oestradiol and can mask the effects of
oestradiol stimulation and the partial agonist effects of some anti-
oestrogens such as tamoxifen (Berthois et al, 1986). Despite the
concerns of phenol red acting as a weak oestrogen the data
consistently show that culture under normal control conditions
does not result in over-expression of GRP78 or XBP1. Addition of
oestradiol to the culture medium at physiological levels shows a
consistent over-expression of GRP78 in a dose-dependant manner.
The UPR is known to confer resistance to anti-cancer agents and
these data support previous in vitro studies, which have shown
that topoisomerase II-directed agents such as doxorubicin and
etoposide are inhibited by UPR activation (Shen et al, 1987;
Hughes et al, 1989; Chatterjee et al, 1995). In clinical studies, a
reduced time to recurrence has been linked to over-expression of
GRP-78 in women with early breast cancer treated with
doxorubicin (Lee et al, 2006), so these findings may be of direct
clinical relevance.
Our data also show for the first time that UPR induction
confers resistance to 5-flurouracil another agent commonly used in
the treatment of breast cancer, usually as part of a multi-agent
regime.
The UPR is currently a stimulating interest within cancer
therapeutics as it is cytoprotective against commonly used anti-
cancer agents such as doxorubicin, 5-FU and cisplatin. Agents that
target the UPR may be clinically useful in either reducing
resistance to the existing anti-cancer drugs or representing a
novel therapeutic target in its own right. Further study of the link
between the UPR and the development of anti-oestrogen resistance
is also needed, to facilitate understanding of why this occurs and
provide strategies to prevent it. Again, UPR targeting agents may
have a function in this field.
ACKNOWLEDGEMENTS
We thank Dr Valerie Corrigall (University College London) for
provision of recombinant GRP78, Yvonne Stephenson and Sian
Leech (Core Histology Service and Department of Human
Nutrition, University of Sheffield) for technical advice and
Dr Christopher Connolly for staining the DCIS sections (Chesterfield
Royal Hospital).
REFERENCES
Al-Rawashdeh F, Scriven P, Cameron IC, Wyld L (2008) The unfolded
protein response is activated in human hepatocellular carcinoma and in
vitro activation is proportional to glucose deprivation. EJSO 34: 1084
Berthois Y, Katzenellbogen JA, Katzellenbogen BS (1986) Phenol red in
tissue culture media is a weak estrogen: implications concerning the
study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA
83(8): 2496–2500
Chatterjee S, Cheng MF, Berger RB, Berger SJ, Berger NA (1995) Effect of
inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78
and subsequent development of resistance to etoposide. Cancer Res 55:
868–873
Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S,
Lieskovsky G, Skinner DG, Lee AS, Pinski J (2007) Glucose-regulated
protein GRP78 is up-regulated in prostate cancer and correlates with
recurrence and survival. Hum Pathol 38: 1547–1552
Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough
R, Rudland PS, Sibson DR (2008) Expression and splicing of the
unfolded protein response gene XBP-1 are significantly associated with
clinical outcome of endocrine-treated breast cancer. Int J Cancer 123:
85–88
Fernandez PM, Tabbara SO, Jacobs LK, Manning FCR, Tsangaris TN,
Schwartz AM, Kennedy KA, Patierno SR (2000) Overexpression of the
glucose-regulated stress gene GRP78 in malignant but not benign human
breast lesions. Breast Cancer Res Treat 59: 15–26
Fu Y, Li J, Lee AS (2007) GRP78/BiP inhibits endoplasmic reticulum BlK
and protects human breast cancer cells against estrogen starvation-
induced apoptosis. Cancer Res 67: 3734–3740
Gilligan DM, Quyyumi AA, Cannon RO (1994) Effects of physiological
levels of estrogen on coronary vasomotor function in postmenopausal
women. Circulation 89: 2545–2551
Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC,
Zhu Y, Zwart A, Wang M, Clarke R (2007) Human X-Box binding
protein-1 confers both estrogen independence and antiestrogen resis-
tance in breast cancer cell lines. FASEB J 7: 1–15
Hammond C, Helenius A (1994) Quality control in the secretory pathway:
retention of a misfolded viral membrane glycoprotein involves cycling
between the ER, intermediate compartment and golgi apparatus. J Cell
Biol 126: 41–52
Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC,
Nicholson RI, Griffiths K (1982) A prognostic index in primary breast
cancer. Br J Cancer 45: 361–366
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex
(ABC) in immunoperoxidase techniques: a comparison between ABC
and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:
577–580
Hughes CS, Shen JW, Subjeck JR (1989) Resistance to etoposide (VP-16)
induced by three glucose related stresses in Chinese hamster ovary cells.
Cancer Res 49: 4452–4454
Kiang JG, Gist ID, Tsokos GC (1997) 17b-estradiol-induced increases in
glucose-regulated protein 78kD and 94kD protect human breast cancer
T47-D cells from thermal injury. Chin J Physiol 40: 213–219
Koumenis C, Wouters BG (2006) Translating tumor hypoxia: unfolded
protein response (UPR) – dependent and UPR-independent pathways.
Mol Cancer Res 4: 423–436
Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J (1988) The
presence of malfolded proteins in the endoplasmic reticulum signals the
induction of glucose regulated proteins. Nature 332: 462–464
Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS (2006) GRP78 as a
novel predictor of responsiveness to chemotherapy in breast cancer.
Cancer Res 66: 7849–7853
Lim JTE, Joe AK, Suzue M, Shimizu M, Masuda M, Weinstein IB (2006)
Sulindac sulfide and exisulind inhibit expression of the estrogen and
progesterone receptors in human breast cancer cells. Clin Cancer Res 12:
3478–3484
Schlappack OK, Zimmermann A, Hill RP (1991) Glucose starvation and
acidosis: effect on experimental metastatic potential, DNA content and
MTX resistance of murine tumour cells. Br J Cancer 64: 663–670
Scriven P, Brown NJ, Pockley AG, Wyld L (2007a) The unfolded protein
response and cancer: a brighter future unfolding? J Mol Med 85: 331–341
Scriven P, Ritchie J, Wyld L (2007b) UPR activation in the human gastric
adenocarcinoma cell line AGS enhances resistance to the commonly used
anticancer agents cisplatin, doxorubicin and 5FU. Cell Stress Chaperones
12: 358
Scriven P, Wright JL, Burn L, Wyld L, Peterson M, Cameron I (2008) The
unfolded protein response is activated in human pancreatic adenocarci-
nomas and affects chemo sensitivity in vitro. Pancreatology 8: 82
Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessener T, Subjeck J (1987)
Coinduction of glucose regulated proteins and doxorubicin resistance in
Chinese hamster cells. Proc Natl Acad Sci USA 84: 3278–3282
Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai
M, Wakatsuki T, Matsubara O, Yamamoto N, Yamamoto M (2003)
Activiation of the ATF6, XBP1 and grp78 genes in human hepatocellular
carcinoma: a possible involvement of the ER stress pathway in
hepatocarcinogenesis. J Hepatol 38: 605–614
Sørlie T, Perou CM, Tibshirani R, Asa T, Geisler S, Johnsen H,
Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T,
The unfolded protein response in breast cancer
P Scriven et al
1697
British Journal of Cancer (2009) 101(10), 1692 – 1698& 2009 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-
Dale A-L (2001) Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl Acad
Sci 98: 10869–10874
Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, Morita M,
Yasumoto K (2005) Expression of endoplasmic reticulum molecular
chaperone Grp78 in human lung cancer and its clinical significance.
Lung Cancer 49: 55–62
Warburg O (1956) On the origin of cancer cells. Science 123: 309–314
Wei J-Y, Hendershot LM (1995) Characterisation of the nucleotide binding
properties and ATPase activity of recombinant hamster BiP purified
from bacteria. J Biol Chem 270: 26670–26677
Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S, Xie K
(2006) Association of elevated GRP78 expression with increased lymph
node metastasis and poor prognosis in patients with gastric cancer. Clin
Exp Metastasis 23: 401–410
The unfolded protein response in breast cancer
P Scriven et al
1698
British Journal of Cancer (2009) 101(10), 1692 – 1698 & 2009 Cancer Research UK
T
ra
n
sla
tio
n
a
l
T
h
e
ra
p
e
u
tic
s
